THOMAS G WIGGANS
CIK 1208907 · Chief Executive Officer · last filed 2026-06-12
THOMAS G WIGGANS is a Chief Executive Officer who has filed 114 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for ANNX, was dated Jul 15, 2026. Across all open-market trades the lifetime net is −$7.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.47M
10
114
-$7.30M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PCRX | Director | — | $26.81 | — | $0 | 1 | 2026-06-12 |
| JSPRW | Director | 46,000 | $0.01 | $557 | $130.7K | 7 | 2025-09-24 |
| ANNX | Director | — | $4.97 | — | $0 | 5 | 2025-06-09 |
| CymaBay Therapeutics, Inc. (CBAY) Delisted | Director | — | $32.48 | — | $0 | 5 | 2024-03-22 |
| PARDES BIOSCIENCES, INC. (PRDS) Delisted | Chief Executive Officer | 0 | $2.16 | $0 | $53.0K | 6 | 2023-08-31 |
| Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Director | 0 | $20.01 | $0 | $0 | 4 | 2022-10-14 |
| DERM | CEO & Chairman of the Board | 233,506 | $6.31 | $1.47M | -$5.33M | 40 | 2019-08-19 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | Director | 8,115 | — | — | -$2.07M | 19 | 2013-05-23 |
| Pernix Sleep, Inc. (SOMX) Delisted | Director | 15,286 | — | — | -$80.9K | 13 | 2012-07-03 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | — | $0.18 | — | $0 | 4 | 2011-06-03 |
Recent Filings
114 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-15 | ANNX | Notice (144) | −2,000 | -$12.6K | EDGAR |
| 2026-07-14 | ANNX | Notice (144) | −1,000 | -$5.6K | EDGAR |
| 2026-06-12 | PCRX | Grant (A) | — | $0 | EDGAR |
| 2025-09-24 | JSPRW | Buy (P) | +41,000 | $99.6K | EDGAR |
| 2025-07-03 | JSPRW | Grant (A) | — | $0 | EDGAR |
| 2025-06-09 | ANNX | Grant (A) | — | $0 | EDGAR |
| 2024-06-10 | JSPRW | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | ANNX | Grant (A) | — | $0 | EDGAR |
| 2024-03-22 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Disp (D) | — | $0 | EDGAR |
| 2024-01-26 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.